Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHANIE E SMITH-PHILLIPS

Allopathic & Osteopathic Physicians Dermatology

NPI
1518922509
CMS profile
159999
Location
MOUNT PLEASANT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,260.91

95 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,260.91 95

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHANIE E SMITH-PHILLIPS

NPI 1518922509 · CMS profile ID 159999

Allopathic & Osteopathic Physicians / Dermatology

MOUNT PLEASANT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518922509?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHANIE E SMITH-PHILLIPS, NPI 1518922509, CMS profile ID 159999. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518922509?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). STEPHANIE E SMITH-PHILLIPS, NPI 1518922509, CMS profile ID 159999. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518922509?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
STEPHANIE E SMITH-PHILLIPS, NPI 1518922509, CMS profile ID 159999, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–95 of 95 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518922509?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

95 matching records · $2,260.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 95 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–95 of 95.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Almirall LLC $34.5606/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120643243 CMS
ABBVIE INC. $22.5506/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106128418 CMS
PFIZER INC. $18.9606/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131735692 CMS
Regeneron Healthcare Solutions, Inc. $30.8806/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114182269 CMS
Arcutis Biotherapeutics, Inc. $15.2706/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121074555 CMS
Janssen Biotech, Inc. $20.5906/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078635999 CMS
REVANCE THERAPEUTICS, INC. $21.5306/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147929535 CMS
Galderma Laboratories, L.P. $21.0006/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145329215 CMS
Arcutis Biotherapeutics, Inc. $14.6605/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121074557 CMS
GENZYME CORPORATION $34.1405/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139982148 CMS
Dermavant Sciences, Inc. $23.6405/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127936791 CMS
UCB, Inc. $17.6805/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143171162 CMS
LEO Pharma Inc. $22.7405/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152652065 CMS
Janssen Biotech, Inc. $16.0805/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078636061 CMS
E.R. Squibb & Sons, L.L.C. $16.5505/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101410699 CMS
Novartis Pharmaceuticals Corporation $24.1905/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087311217 CMS
PFIZER INC. $14.7704/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131725390 CMS
E.R. Squibb & Sons, L.L.C. $18.8004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101410697 CMS
ABBVIE INC. $16.5604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106128416 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.0004/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118042564 CMS
Dermavant Sciences, Inc. $22.4404/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127936787 CMS
Arcutis Biotherapeutics, Inc. $13.1304/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121074559 CMS
Amgen Inc. $26.1903/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117688406 CMS
PFIZER INC. $14.5203/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131719054 CMS
Janssen Biotech, Inc. $18.4003/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078636141 CMS
ABBVIE INC. $29.5903/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106128414 CMS
GENZYME CORPORATION $33.2403/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139982138 CMS
Incyte Corporation $24.1403/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141316569 CMS
Almirall LLC $34.0002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120643223 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $23.8102/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153817467 CMS
Dermavant Sciences, Inc. $22.1702/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127936783 CMS
E.R. Squibb & Sons, L.L.C. $21.1702/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101410683 CMS
Novartis Pharmaceuticals Corporation $25.7202/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087311213 CMS
LEO Pharma Inc. $19.1902/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152652063 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.2902/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118042568 CMS
Janssen Biotech, Inc. $14.9102/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078636112 CMS
Verrica Pharmaceuticals Inc. $15.2902/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118387000 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.0301/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152203965 CMS
Novartis Pharmaceuticals Corporation $24.7501/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087311211 CMS
Regeneron Healthcare Solutions, Inc. $21.8901/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114182261 CMS
Janssen Biotech, Inc. $16.0701/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078636214 CMS
PFIZER INC. $15.0401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131706834 CMS
LEO Pharma Inc. $19.8001/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152652061 CMS
E.R. Squibb & Sons, L.L.C. $19.4201/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101410681 CMS
Dermavant Sciences, Inc. $19.9801/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127936780 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,384.47 89
PY2020 $664.19 44
PY2021 $1,414.50 69
PY2022 $1,370.85 63
PY2023 $1,999.78 85
PY2024 $2,260.91 95
PY2025 $2,184.90 81

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $182,805.98 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

90 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $2,083.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524990
Principal investigator 1 Incyte Corporation $2,083.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524994
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525056
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525064
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525068
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525072
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525076
Principal investigator 1 Incyte Corporation $53.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525080
Principal investigator 1 Incyte Corporation $1,943.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525116
Principal investigator 1 Incyte Corporation $1,943.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525120
Principal investigator 1 Incyte Corporation $1,785.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525130
Principal investigator 1 Incyte Corporation $1,810.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525134
Principal investigator 1 Incyte Corporation $1,539.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525147
Principal investigator 1 Incyte Corporation $133.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525165
Principal investigator 1 Incyte Corporation $1,896.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525285
Principal investigator 1 Incyte Corporation $3,111.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525289
Principal investigator 1 Incyte Corporation $2,709.00 12/19/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525293
Principal investigator 1 Incyte Corporation $651.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525029
Principal investigator 1 Incyte Corporation $266.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525084
Principal investigator 1 Incyte Corporation $1,632.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525174
Principal investigator 1 Incyte Corporation $13.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525190
Principal investigator 1 Incyte Corporation $1,164.00 12/18/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525252
Principal investigator 1 SANOFI PASTEUR INC. $2,731.16 12/04/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112458
Principal investigator 1 SANOFI PASTEUR INC. $300.00 12/01/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112880
Principal investigator 1 Incyte Corporation $1,979.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525019
Principal investigator 1 Incyte Corporation $1,979.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525024
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525048
Principal investigator 1 Incyte Corporation $169.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525052
Principal investigator 1 Incyte Corporation $86.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525060
Principal investigator 1 Incyte Corporation $2,065.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525089
Principal investigator 1 Incyte Corporation $2,112.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525093
Principal investigator 1 Incyte Corporation $2,112.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525096
Principal investigator 1 Incyte Corporation $2,112.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525100
Principal investigator 1 Incyte Corporation $194.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525125
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525139
Principal investigator 1 Incyte Corporation $3,280.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525144
Principal investigator 1 Incyte Corporation $2,252.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525152
Principal investigator 1 Incyte Corporation $133.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525156
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525221
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525224
Principal investigator 1 Incyte Corporation $53.00 11/21/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525228
Principal investigator 1 Incyte Corporation $186.00 11/14/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525199
Principal investigator 1 Incyte Corporation $1,088.00 11/14/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525231
Principal investigator 1 SANOFI PASTEUR INC. $19,968.73 11/14/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112848
Principal investigator 1 SANOFI PASTEUR INC. $2,085.37 11/05/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112774
Principal investigator 1 SANOFI PASTEUR INC. $33,843.20 10/31/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112506
Principal investigator 1 Incyte Corporation $2,500.00 10/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525161
Principal investigator 1 Incyte Corporation $1,500.00 10/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525195
Principal investigator 1 Incyte Corporation $10,000.00 10/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525255
Principal investigator 1 Incyte Corporation $2,000.00 10/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525261
Principal investigator 1 Incyte Corporation $5,000.00 10/28/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525281
Principal investigator 1 Incyte Corporation $1,979.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524998
Principal investigator 1 Incyte Corporation $1,979.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525003
Principal investigator 1 Incyte Corporation $194.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525007
Principal investigator 1 Incyte Corporation $194.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525011
Principal investigator 1 Incyte Corporation $194.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525015
Principal investigator 1 Incyte Corporation $2,252.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525033
Principal investigator 1 Incyte Corporation $2,252.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525037
Principal investigator 1 Incyte Corporation $2,252.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525040
Principal investigator 1 Incyte Corporation $2,252.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525044
Principal investigator 1 Incyte Corporation $86.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525104
Principal investigator 1 Incyte Corporation $86.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525108
Principal investigator 1 Incyte Corporation $86.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525112
Principal investigator 1 Incyte Corporation $2,112.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525169
Principal investigator 1 Incyte Corporation $133.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525178
Principal investigator 1 Incyte Corporation $133.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525182
Principal investigator 1 Incyte Corporation $133.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525186
Principal investigator 1 Incyte Corporation $53.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525204
Principal investigator 1 Incyte Corporation $53.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525209
Principal investigator 1 Incyte Corporation $53.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525213
Principal investigator 1 Incyte Corporation $53.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525216
Principal investigator 1 Incyte Corporation $169.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525235
Principal investigator 1 Incyte Corporation $169.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525238
Principal investigator 1 Incyte Corporation $169.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525243
Principal investigator 1 Incyte Corporation $169.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525248
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525265
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525268
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525272
Principal investigator 1 Incyte Corporation $3,280.00 10/22/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240525277
Principal investigator 1 SANOFI PASTEUR INC. $600.00 10/13/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112813
Principal investigator 1 Incyte Corporation $86.00 09/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524970
Principal investigator 1 Incyte Corporation $3,280.00 09/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524975
Principal investigator 1 Incyte Corporation $133.00 09/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524978
Principal investigator 1 Incyte Corporation $194.00 09/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524983
Principal investigator 1 Incyte Corporation $169.00 09/25/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240524987
Principal investigator 1 SANOFI PASTEUR INC. $300.00 06/09/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112702
Principal investigator 1 SANOFI PASTEUR INC. $717.52 05/19/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112594
Principal investigator 1 SANOFI PASTEUR INC. $2,926.54 05/19/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112688
Principal investigator 1 SANOFI PASTEUR INC. $1,512.46 05/16/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112673
Principal investigator 1 SANOFI PASTEUR INC. $14,200.00 05/14/2025 Non-covered Recipient Entity
Delricht Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226112641